Letter to the Editor, Angioimmunoblastic T-cell lymphoma (AITL) originates from T follicular helper (TFH) cells and is widely considered to be an aggressive T-cell neoplasm. Cure rates are low, and relapses are common, with a median overall survival of only three years [1,2,3]. In the 2022 World Health Organization classification [4], the term nodal TFH (nTFH) cell lymphomas unites the subtypes of angioimmunoblastic type, follicular type and a not otherwise specified (NOS) category [5].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Jadee
Contact Jadee, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack